Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
WanburyBOM:524212 -2.68%67 EBITDA Margin % is 16.07% as of Mar. 2026, which is 10% above its 10-year median of 14.67. GuruFocus rates BOM:524212 with a GF Score™ of 67/100 and a GF Value™ of ₹244.17 (Modestly Overvalued). The stock has 6 warning signs investors should review. Among 961 Drug Manufacturers companies, Wanbury ranks better than 59.31% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. Wanbury's EBITDA for the
three
months ended in Mar. 2026 was ₹265 Mil. Wanbury's Revenue for the
three
months ended in Mar. 2026 was ₹1,646 Mil. Therefore, Wanbury's EBITDA margin for the quarter that ended in Mar. 2026 was 16.07%.
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Wanbury EBITDA Margin % Related Terms
Wanbury EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Wanbury's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Wanbury's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Wanbury EBITDA Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Wanbury's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Wanbury's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Wanbury (BOM:524212) has a EBITDA Margin % of 16.07% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Wanbury and its competitors. This is 10% above median its historical median of 14.67. Over the past decade, Wanbury's EBITDA Margin % has ranged from 2.38 to 29.57. According to the industry distribution chart, Wanbury ranks #391 out of 961 companies in the Drug Manufacturers industry, placing it in the top 40.7%.
Is Wanbury's EBITDA Margin % too high?
Wanbury's current EBITDA Margin % of 16.07% is 10% above median its 10-year median of 14.67. Over the past 10 years, this metric has ranged from a low of 2.38 to a high of 29.57. The Drug Manufacturers industry median EBITDA Margin % is 12.39. Wanbury's value of 16.07% is 29.7% above this industry median. Based on the distribution chart, Wanbury ranks #391 out of 961 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Wanbury has a GF Score™ of 67/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Wanbury's EBITDA Margin % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Wanbury ranks #391 out of 961 companies for EBITDA Margin %. This puts Wanbury in the upper half of its industry. The industry median EBITDA Margin % is 12.39. Wanbury's value of 16.07% is 29.7% above this benchmark. Historically, Wanbury's own EBITDA Margin % has ranged from 2.38 to 29.57 over the past decade. While the company's 10-year median is 14.67 vs. the industry median of 12.39, Wanbury has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Drug Manufacturers company?
The median EBITDA Margin % among Drug Manufacturers companies is 12.39, based on 961 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Wanbury's current EBITDA Margin % of 16.07% is 29.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Wanbury and its competitors. For the Drug Manufacturers industry, the median EBITDA Margin % is 12.39 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Wanbury's current EBITDA Margin % is 16.07%, which is 10% above median its own 10-year median of 14.67. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Wanbury stock overvalued right now?
Based on GuruFocus' analysis, Wanbury (BOM:524212) is currently considered Modestly Overvalued. The stock's GF Value™ is ₹244.17, compared to a current price of ₹279.10 — trading 14.3% above its estimated fair value. The current EBITDA Margin % is 16.07%, which is 10% above median its 10-year median of 14.67 and 29.7% above the Drug Manufacturers industry median of 12.39. Wanbury's overall GF Score™ is 67/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Wanbury (BOM:524212), the current EBITDA Margin % is 16.07% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Wanbury (BOM:524212) Overvalued in 2026?
Based on GuruFocus' analysis, Wanbury stock appears to be overvalued.
The current stock price of ₹279.10 is trading 14.3% above its estimated GF Value™ of ₹244.17.
GuruFocus considers Wanbury to be Modestly Overvalued.
Key valuation signals for BOM:524212:
EBITDA Margin %: 16.07% (10% above median its 10-year median of 14.67)
GF Value™: ₹244.17 vs. price of ₹279.10 (14.3% above fair value)
Industry Position: 29.7% above the Drug Manufacturers median (#391 of 961)
No single metric tells the full story. See the BOM:524212 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Wanbury Ltd is engaged in the business of pharmaceutical and related activities, including research. Some of the company's products include Cpink 50mg tablets, Rabiplus capsules, and Folinine softgels, among others. The company has one segment of activity, namely, Pharmaceuticals and related products. It generates revenue from contracts with customers through the sale of manufactured and traded goods. Geographically, key revenue is generated from outside India.
67GF Score
Get the complete analysis for BOM:524212
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:524212 has been successfully added to your 
